[20200113]LSB10392_CMS医院价格透明度最终规则及相关法律质疑.pdf

CRS Legal Sidebar Prepared for Members and Committees of Congress Legal SidebarLegal Sidebari i CMSs Hospital Price Transparency Final Rule and Related Legal Challenge January 13, 2020 Addressing the rising cost of health care, including reducing the prices consumers pay for health care services and products, has been an area of interest for Congress and the Trump Administration. One approach is promoting price transparency, which proponents argue could lower costs by enabling healthcare consumers to comparison shop, prompting providers of healthcare services and products to offer more competitive pricing. The Administration has announced price transparency proposals both in the context of prescription drugs and health care provider services. Earlier in 2019, for instance, the Centers for Medicare and Medicaid Services (CMS) issued a final rule that would have required direct-to-consumer television advertisements for certain prescription drugs to disclose the drugs list prices. Several pharmaceutical manufacturers sued to challenge the rule, and the U.S. District Court for the District of Columbia agreed, in a decision that the U.S. Department of Health and Human Services (HHS) has